Sun Pharma Advanced Research Company · NSE: SPARC · BSE: 532872
Q1 FY26 results · Apr–Jun 2025
Sun Pharma Advanced Research Company reported revenue from operations of ₹9.64 crore (down 42.7% from Q1 FY25) and net loss of ₹51.87 crore for Q1 FY26 (Apr–Jun 2025), on a consolidated basis.
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 9.64 | 16.81 | −42.7% | 27.19 | −64.5% |
| Other income | 9.14 | 1.56 | +485.9% | 0.00 | — |
| Total income | 18.78 | 18.37 | +2.2% | 27.19 | −30.9% |
| Profit before tax | (51.81) | (95.50) | Loss narrowed | (60.67) | Loss narrowed |
| Net profit for the period | (51.87) | (95.90) | Loss narrowed | (59.77) | Loss narrowed |
| EPS, basic (₹) | (1.60) | (2.96) | Loss narrowed | (1.84) | Loss narrowed |
| Net margin (%) | -538.1 | -570.5 | -219.8 |
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 9.64 | 16.81 | −42.7% | 27.19 | −64.5% |
| Other income | 9.02 | 1.56 | +478.2% | 0.00 | — |
| Total income | 18.66 | 18.37 | +1.6% | 27.19 | −31.4% |
| Profit before tax | (52.03) | (96.84) | Loss narrowed | (60.98) | Loss narrowed |
| Net profit for the period | (52.03) | (96.84) | Loss narrowed | (60.98) | Loss narrowed |
| EPS, basic (₹) | (1.60) | (2.98) | Loss narrowed | (1.88) | Loss narrowed |
| Net margin (%) | -539.7 | -576.1 | -224.3 |
Consolidated
- Filed with BSE
- 04 Aug 2025, 14:02 IST
- Board meeting
- 04 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 04 Aug 2025, 14:02 IST
- Board meeting
- 04 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE